Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial
Hannah D Smith, J. Lally, Alison Moy, Julie Ryan‐Wolf, A. de Benedetto
JEADV Clinical Practice